RECRUITING Not applicable ClinicalTrials.gov

Effect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes

Sponsor: Shanghai 6th People's Hospital • ClinicalTrials.gov ID: NCT07007676

Registry updated: 2026-09-08

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this clinical trial is to learn if continuous glucose monitoring system works to improve glucose control in non-insulin-treated older adults with type 2 diabetes. The main questions it aims to answer are: * Dose the use of continuous glucose monitoring system improve glucose control in older adults with type 2 diabetes treated with oral antidiabetic drugs only? * Dose the use of continuous glucose monitoring system affect psychological outcomes in older adults with type 2 diabetes treated with oral antidiabetic drugs only? Researchers will compare continuous glucose monitoring to standard blood glucose monitoring to see if continuous glucose monitoring works better in glucose management. Participants will: * Wear continuous glucose monitoring every 2 months or standard blood glucose monitoring for 6 months * Visit the clinic once every 2 months for follow-up * Keep a diary of their blood glucose when continuous glucose monitoring was not used

Interventions

real-time CGM (Device)
real-time CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.

Eligibility criteria

Inclusion Criteria: * Age ≥ 60 years at the time of screening; * Diagnosed with type 2 diabetes mellitus; * Treated with two or more oral antidiabetic drugs with a stable medication regimen (medication classes) during the 3 months prior to entry; * Suboptimal glycemic control, defined as HbA1c ≥ 7.5% and ≤ 10% at screening or within 30 days prior to screening visit; * Has a smart phone compatible with CGM and BGM systems; * Willing and able to provide written informed consent; * At least 240 hours (10 out of 14 days) of sensor glucose data from the blinded CGM pre-randomization phase. Exclusion Criteria: * Use of insulin or Glucagon-Like Peptide-1 （GLP-1） receptor agonists within 3 months prior to screening; * Use of any CGM device within 3 months prior to screening; * Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area; * Considered unsuitable for participation by the investigators, including but not limited to individuals with dementia, psychiatric disorders, extreme visual or hearing impairment that would impair ability to use real-time CGM assessed; * Planned surgery or other procedures within the next 6 months that may interfere with scheduled follow-up visits; * Current or anticipated acute uses of glucocorticoids (oral, injectable, or IV), that will affect glycemic control; * Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2; * Participation in any other clinical trial within 3 month prior to screening, or concurrently enrolled, or planning to participate in another trial during the study period.

Conditions

Diabetes Mellitus Type 2

Locations

Shenzhen Jiangangshan Health Service Center — Shenzhen, Guandong, China
Shenzhen Fifth Avenue Health Service Station — Shenzhen, Guangdong, China
Shenzhen Haifu Health Service Station — Shenzhen, Guangdong, China
Shenzhen Haile Huafu Health Service Station — Shenzhen, Guangdong, China
Shenzhen Haiyu Health Service Station — Shenzhen, Guangdong, China
Shenzhen Jiaan Health Service Station — Shenzhen, Guangdong, China
Shenzhen Jiari Mingju Health Service Station — Shenzhen, Guangdong, China
Shenzhen Xinan Lake Health Service Station — Shenzhen, Guangdong, China
Shenzhen Xingdong Health Service Station — Shenzhen, Guangdong, China
Shenzhen Zhongliang Chuangxin Health Service Station — Shenzhen, Guangdong, China
Guantian Community Health Service Station — Shenzhen, Guangdong, China
Huiyu Mingdu Community Health Service Station — Shenzhen, Guangdong, China
Langxin Community Health Service Station — Shenzhen, Guangdong, China
Luozu Community Health Service Center — Shenzhen, Guangdong, China
Shuitian Health Service Center — Shenzhen, Guangdong, China
Tianbao Community Health Service Center — Shenzhen, Guangdong, China
Shenzhen Buxin Community Health Service Center — Shenzhen, Guangdong, China
Shenzhen Dalang Community Health Service Center — Shenzhen, Guangdong, China
Shenzhen Haihua Community Health Service Center — Shenzhen, Guangdong, China
Shenzhen Haile Community Health Service Station — Shenzhen, Guangdong, China
Shenzhen Pingzhou Community Health Service Center — Shenzhen, Guangdong, China

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment